Upcoming Medical Policies
BlueCross BlueShield of Tennessee

Each medical policy listed below will become effective on the date indicated, and will be included in the Medical Policy Manual for BlueCross BlueShield of Tennessee on that effective date.

Medical policies are developed using an evidence-based evaluation process. The medical evidence used in this process comes from several sources, including independent medical technology review organizations, the peer reviewed medical literature, and opinions from appropriate network specialists. All Medical Policies are reviewed by a panel of internal and external physicians before being adopted by the company.

Topics due to be included in the Medical Policy Manual on 5/13/2017

Topics due to be included in the Medical Policy Manual on 6/10/2017

Topics due to be included in the Medical Policy Manual on 6/21/2017

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Topics due to be included in the Medical Policy Manual on 5/13/2017:

Breast Cancer Gene Expression Assays

Intestinal Transplantation

Spinal Cord Stimulation / Peripheral Subcutaneous Field Stimulation for the Treatment of Pain

Topics due to be included in the Medical Policy Manual on 6/10/2017:

Homocysteine Testing in the Screening, Diagnosis, and Management of Dyslipidemia and Cardiovascular Disease and Venous Thromboembolic Disease

Topics due to be included in the Medical Policy Manual on 6/21/2017:

Osteochondral Allografting


Last Review Date 4/12/2017

Medical Policy Comments:

Please reference the policy name in your comments.
To submit comments about the upcoming Medical policies:
Click the “Medical Policy Comments” above or click here: Comments or Feedback.

Comments can also be mailed to:

BlueCross BlueShield of Tennessee
Medical Policy
1 Cameron Hill Circle
Chattanooga, TN 37402